• Explore /
  • Poster
  • / Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.

Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.

Abstract Poster

Authors

null

Christopher Ryan Heery

Laboratory of Tumor Immunology and Biology, NCI, NIH, Bethesda, MD

Christopher Ryan Heery , Geraldine Helen O'Sullivan Coyne , Jennifer L. Marte , Harpreet Singh , Lisa M Cordes , Ravi Amrit Madan , Renee Nicole Donahue , Italia Grenga , Lauren Lepone , Berend Neuteboom , Isabell Speit , Kevin M. Chin , Jeffrey Schlom , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3055)

DOI

10.1200/jco.2015.33.15_suppl.3055

Abstract #

3055

Poster Bd #

381

Abstract Disclosures

Similar Posters

First Author: Christopher Ryan Heery

First Author: Kohei Shitara

First Author: Stéphane Champiat

First Author: Thorsten Oliver Goetze